Change Language
Sevelamer Tablet

Product Details:

  • Purity 99.0% min
  • Appearance White or off-white tablets
  • Solubility Insoluble in water; swells in contact with water
  • CAS No 52757-95-6
  • Molecular Formula (C8H16ClNO4)x
  • HS Code 30049099
  • Assay 95.0%105.0%
4500 INR/Strip
X

Sevelamer Tablet Price And Quantity

  • 1 Box
  • 4500 INR/Strip

Sevelamer Tablet Product Specifications

  • Store in a cool dry place below 25C and keep away from direct sunlight
  • 95.0%105.0%
  • 30049099
  • (C8H16ClNO4)x
  • 52757-95-6
  • Insoluble in water; swells in contact with water
  • Phosphate binder for treating hyperphosphatemia in patients with chronic kidney disease (CKD)
  • 99.0% min
  • White or off-white tablets
  • Pharmaceutical Product
  • Other
  • 24 months

Sevelamer Tablet Trade Information

  • 1000 Box Per Month
  • 7 Days
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
  • All India

Product Description

Sevelamer Tablet


 

Product Details:

Minimum Order Quantity 100 Box
Packaging Size 10 Tablets
Product Type Finished Product
Usage Commercial, Clinical, Hospital, Personal


We are leading exporter and manufacturer of Sevelamer Tablet.

Uses


Sevcar 400 mg tablet is used in the treatment of increased phosphate levels in blood


How it works


Sevcar 400 mg tablet acts by binding the phosphate molecule from food in the digestive tract and decreases its absorption and consequently lowers the phosphate levels in the blood.

Common side effects


Nausea, Vomiting, Abdominal pain upper, Flatulence, Constipation, Diarrhoea, Dyspepsia


Sevelamer Tablet exporter, Sevelamer Tablet manufacturer

Sevelamer Tablet supplier, Sevelamer Tablet manufacturer in India,

Sevelamer Tablet exporter in India.

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

Other Products in 'Nephrology Medicines' category



We deal in bulk foreign inquiries.
Back to top